Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 28, 2005

Conditions
LymphomaLeukemiaCancer
Interventions
DRUG

MEDI-507

Trial Locations (11)

19107

Kimmel Cancer Center, Thomas Jefferson University, Philadelphia

20007

Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington D.C.

21201

University of Maryland School of Medicine, Greenebaum Cancer Center, Baltimore

27517

Wake Forest University Health Sciences, Winston-Salem

33612

H. Lee Moffitt Cancer Ctr & Research Institute Div of Hem/Onc, Tampa

63110

Washington University, St Louis

77030

M.D. Anderson Cancer Center, Houston

89135

Nevada Cancer Institute, Las Vegas

90033

USC/Norris Cancer Center, Los Angeles

06520

Yale Cancer Center, New Haven

02111

Tufts New England Medical Center, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY